BioCentury | Aug 1, 2020
Product Development

July 31 Quick Takes: FDA approves MorphoSys’ tafasitamab; Truvian, AbbVie, Boehringer, Lilly, Alector, Henlius-Accord, Ascletis, Roche, Merck

...other prevalent viruses. AbbVie’s migraine therapy headed for FDA The Phase III ADVANCE trial of atogepant...
...plans to move forward with regulatory submissions in the U.S. and other countries (see “ Atogepant...
...RO5185426 (Compound #), RG7204 (Compound #), R7204 (Compound #), PLX4032 (Compound #), vemurafenib (Generic) atogepant (AGN-241689, MK-8031) Eli...
BioCentury | Sep 8, 2018
Product Development

Data distribution

...placebo groups in two Phase III studies of ubrogepant and a Phase IIb study of atogepant...
BioCentury | Jun 14, 2018
Clinical News

Allergan's atogepant meets in Phase IIb/III to prevent migraine

...Allergan plc (NYSE:AGN) said all doses of oral atogepant (MK-8031) met the primary endpoint in the...
...of hepatotoxicity with atogepant, which had a similar liver safety profile to that of placebo. Atogepant...
...over 12 weeks Status: Phase IIb/III data Milestone: NA Jaime De Leon Aimovig, erenumab (AMG 334) atogepant (AGN-241689, MK-8031) galcanezumab...
BioCentury | Jun 11, 2018
Clinical News

Allergan's atogepant meets in Phase IIb/III to prevent migraine

...Allergan plc (NYSE:AGN) said all doses of oral atogepant (MK-8031) met the primary endpoint in the...
...of hepatotoxicity with atogepant, which had a similar liver safety profile to that of placebo. Atogepant...
...to prevent headaches in adult patients with chronic migraine. Jaime De Leon Aimovig, erenumab (AMG 334) atogepant (AGN-241689, MK-8031) galcanezumab...
BioCentury | May 4, 2018
Clinical News

Allergan reports mixed data for acute migraine candidate in second Phase III

...throughout 2018. In 2015, Allergan licensed exclusive, worldwide rights to migraine candidates ubrogepant and atogepant (MK-8031...
...oral calcitonin gene-related peptide (CGRP) receptor antagonists. Top-line data from a Phase IIb trial of atogepant...
BioCentury | Apr 27, 2018
Clinical News

Allergan reports mixed Phase III data for acute migraine candidate

...throughout 2018. In 2015, Allergan licensed exclusive, worldwide rights to migraine candidates ubrogepant and atogepant (MK-8031...
...oral calcitonin gene-related peptide (CGRP) receptor antagonists. Top-line data from a Phase IIb trial of atogepant...
BioCentury | Feb 9, 2018
Clinical News

Allergan's ubrogepant meets in Phase III for acute migraine

...and nausea. In 2015, Allergan licensed exclusive, worldwide rights to migraine candidates ubrogepant and atogepant (MK-8031...
...oral calcitonin gene-related peptide (CGRP) receptor antagonists. Top-line data from a Phase IIb trial of atogepant...
...and nausea Status: Phase III data Milestone: Additional Phase III data (2018); submit NDA (2019) Allison Johnson atogepant ubrogepant Allergan...
BioCentury | Feb 7, 2018
Clinical News

Allergan's ubrogepant meets in Phase III for acute migraine

...throughout 2018. In 2015, Allergan licensed exclusive, worldwide rights to migraine candidates ubrogepant and atogepant (MK-8031...
...oral calcitonin gene-related peptide (CGRP) receptor antagonists. Top-line data from a Phase IIb trial of atogepant...
...of $3.20-$3.40 and revenue at $3.5-$3.6 billion. The Street was expecting $3.71 and $3.7 billion. Allison Johnson atogepant ubrogepant Allergan...
BioCentury | Sep 19, 2016
Product Development

Getting ahead of headache

...antagonist ubrogepant in Phase III testing to treat migraine, and small molecule CGRP receptor antagonist atogepant...
...receptor antagonist is Allergan plc's ubrogepant. Allergan acquired ubrogepant and the oral CGRP receptor antagonist atogepant...
...Phase III testing for acute migraine. Allergan plans to begin a Phase IIb study of atogepant...
BioCentury | Aug 17, 2015
Product Development

Structure knows best

...ALD403 mAb subcutaneous Migraine Ph I Allergan plc (NYSE:AGN) / Merck & Co. Inc. (NYSE:MRK) MK-8031...
Items per page:
1 - 10 of 12